Clinical trial · Interventional
Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases
Raltitrexed and Oxaliplatin and Lipiodol Transcatheter Arterial Chemoembolization for Advanced Colorectal Cancer
NCT01959061CI-TRIAL-00026401TACEunknownPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the efficacy and safety of Raltitrexed for advanced colorectal cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer Metastatic | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| lipiodol | Drug | — | UNRESOLVED |
| Oxaliplatin | Drug | Oxaliplatin | ALIAS |
| Raltitrexed | Drug | Raltitrexed | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Raltitrexed and Oxaliplatin
- description
- Raltitrexed and Oxaliplatin were mixed with 10-15 ml lipiodol by arterial chemoembolization on day 1 and during each 28-day cycle.
- interventionNames
- Drug: Raltitrexed
- Drug: Oxaliplatin
- Drug: lipiodol
Primary outcomes (1)
- measure
- Progression-free survivial
- timeFrame
- 8 months after last patient randomized
- description
- From date of randomization until date of first documented PD, date of death
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Histologically confirmed colorectal adenocarcinoma 2. Disease limited to the liver Unresectable disease by surgery or other local therapies 3. Age \>18 years 4. ECOG performance status 0-2,Child pugh A or B 5. Expected survival ≥ 3 months 6. Adequate hematological, hepatic, and renal function Exclusion Criteria: 1. Pregnant or lactating women 2. Patients with severe organ dysfunction or failure 3. With severe cardiovascular disease, or mental 4. Extraliver metastases
References
Publications (0)
Data not yet available
No reference posted for this study.